**Core Concept**
The metabolic syndrome is a cluster of conditions including high blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels, which together increase the risk of heart disease, stroke, and diabetes. This condition is often associated with the use of certain medications that promote weight gain or have adverse effects on lipid profiles.

**Why the Correct Answer is Right**
The metabolic syndrome is most commonly associated with the use of thiazolidinediones, a class of medications that are used to treat type 2 diabetes. Thiazolidinediones, such as pioglitazone and rosiglitazone, work by activating the peroxisome proliferator-activated receptor-gamma (PPAR-γ) receptor, which regulates the expression of genes involved in glucose and lipid metabolism. Activation of PPAR-γ leads to increased insulin sensitivity and glucose uptake in peripheral tissues, but it also promotes lipogenesis and adipocyte differentiation, resulting in increased body weight and lipid levels.

**Why Each Wrong Option is Incorrect**
**Option A:** Statins are actually associated with a reduced risk of metabolic syndrome due to their pleiotropic effects, including improved lipid profiles and anti-inflammatory properties.
**Option B:** Metformin is a first-line medication for type 2 diabetes and is generally not associated with weight gain or metabolic syndrome.
**Option C:** SGLT-2 inhibitors are a newer class of diabetes medications that promote glucose excretion in the urine and are not typically associated with metabolic syndrome.

**Clinical Pearl / High-Yield Fact**
When prescribing medications for type 2 diabetes, clinicians should be aware of the potential risk of metabolic syndrome, particularly with thiazolidinediones, and closely monitor patients for signs of weight gain, dyslipidemia, and other cardiovascular risk factors.

**Correct Answer:** C. Thiazolidinediones